PLEASE NOTE

Microsoft has ended support for its pre-IE11 browsers as of January 2016 and will be discontinuing IE11 support in August 2021.

If you are seeing this message, you are viewing the site on one of these unsupported browsers. We only support the recent versions of major browsers such as Chrome, Firefox, Safari, and Edge.

Thank you.

(click to close and continue using this browser)

Sign InDues Join Donate Privacy Contact Search
Home News Scrip

Scrip

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below.

John Lezcano
Corporate Account Manager
M: (631) 807-4971
John.lezcano@informa.com

Pharma intelligence | informa
P: (212) 652-2678
pharmaintelligence.informa.com

Scrip
Friday, September 29, 2023
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers...
Friday, September 29, 2023
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the...
Friday, September 29, 2023
Early-stage data with Structure’s oral GSBR-1290 shows weight loss of 4.9% at four weeks, which appears to top Lilly’s oral...
Friday, September 29, 2023
Friday, September 29, 2023
The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for...
Thursday, September 28, 2023
After failing in a Phase II trial in social anxiety disorder, Bionomics thinks mid-stage data for BNC210 in post-traumatic stress...
Thursday, September 28, 2023
The company announced topline results for MARIPOSA in EGFR-mutant NSCLC, showing positive progression-free survival and a favorable trend on overall...
Thursday, September 28, 2023
CD47 was once seen as one of the hottest properties in immunotherapy, but multiple setbacks have tempered enthusiasm for targeting...
Thursday, September 28, 2023
Thursday, September 28, 2023
Recent executive moves in the industry include new C-suite hires at Editas Medicines, Royalty Pharma and Faron Pharmaceuticals.